CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
A011203 | Alliance | A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic; Estrogen Receptor Positive; HER2 Negative Breast Cancer | Adult CIRB - Early Phase Emphasis | Available to Open |
A171901 | Alliance | Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist's/Patient's Choice) | Cancer Prevention and Control CIRB | Available to Open |
EAY191-A3 | Alliance | A ComboMATCH Treatment Trial: Palbociclib and Binimetinib in RAS-Mutant Cancers | Adult CIRB - Early Phase Emphasis | Available to Open |
A081105 | Alliance | Randomized Study of Erlotinib Vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) | Adult CIRB - Late Phase Emphasis | Available to Open |
A031701 | Alliance | A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (DDGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations | Adult CIRB - Late Phase Emphasis | Available to Open |
A041701 | Alliance | A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy | Adult CIRB - Late Phase Emphasis | Available to Open |
A091603 | Alliance | A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | Adult CIRB - Late Phase Emphasis | Completed |
A011801 | Alliance | The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinb | Adult CIRB - Late Phase Emphasis | Available to Open |
A092104 | Alliance | A Randomized Phase 2/3 Study of Olaparib plus Temozolomide versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma after Progression on Prior Chemotherapy | Adult CIRB - Late Phase Emphasis | Available to Open |
A031501 | Alliance | Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (Ambassador) Versus Observation | Adult CIRB - Late Phase Emphasis | Available to Open |